# Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

> **NCT05116540** · PHASE2 · COMPLETED · sponsor: **Hope Biosciences Research Foundation** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** HB-adMSCs
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05116540
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2024-06-04
- **Final completion:** 2024-06-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116540, "Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05116540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*